MX2023009555A - Composiciones de la forma iv esencialmente pura de n-((r)-2,3-dihidroxipropoxi)-3,4-difluoro-2-(2-fluoro-4-yodo-feni lamino)-benzamida y usos de estas. - Google Patents
Composiciones de la forma iv esencialmente pura de n-((r)-2,3-dihidroxipropoxi)-3,4-difluoro-2-(2-fluoro-4-yodo-feni lamino)-benzamida y usos de estas.Info
- Publication number
- MX2023009555A MX2023009555A MX2023009555A MX2023009555A MX2023009555A MX 2023009555 A MX2023009555 A MX 2023009555A MX 2023009555 A MX2023009555 A MX 2023009555A MX 2023009555 A MX2023009555 A MX 2023009555A MX 2023009555 A MX2023009555 A MX 2023009555A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydroxypropoxy
- benzamide
- difluoro
- fluoro
- pure form
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/018378 WO2022177556A1 (en) | 2021-02-17 | 2021-02-17 | Compositions of essentially pure form iv of n-((r)-2,3- dihydroxypropoxy)-3,4-difluoro-2- (2-fluoro-4-iodophenylamino)- benzamide and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009555A true MX2023009555A (es) | 2023-11-10 |
Family
ID=74860567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009555A MX2023009555A (es) | 2021-02-17 | 2021-02-17 | Composiciones de la forma iv esencialmente pura de n-((r)-2,3-dihidroxipropoxi)-3,4-difluoro-2-(2-fluoro-4-yodo-feni lamino)-benzamida y usos de estas. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4294789A1 (ja) |
| JP (1) | JP2024507822A (ja) |
| KR (1) | KR20230148177A (ja) |
| CN (1) | CN117500781A (ja) |
| AR (1) | AR124907A1 (ja) |
| AU (1) | AU2021428932A1 (ja) |
| CA (1) | CA3211395A1 (ja) |
| IL (1) | IL304974A (ja) |
| MX (1) | MX2023009555A (ja) |
| TW (1) | TW202245746A (ja) |
| WO (1) | WO2022177556A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023223205A1 (en) | 2022-05-17 | 2023-11-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of mirdametinib and process for preparation thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20053496B (en) | 2000-07-19 | 2005-04-25 | Warner Lambert Co | Oxygenated Esters of 4-Iodo Phenylamino Benzhydroxamic Acids |
| AU2004283148A1 (en) | 2003-10-21 | 2005-05-06 | Warner-Lambert Company Llc | Polymorphic form of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
| WO2006134469A1 (en) | 2005-06-14 | 2006-12-21 | Warner-Lambert Company Llc | Methods of preparing mek inhibitor |
-
2021
- 2021-02-17 KR KR1020237030268A patent/KR20230148177A/ko unknown
- 2021-02-17 IL IL304974A patent/IL304974A/en unknown
- 2021-02-17 MX MX2023009555A patent/MX2023009555A/es unknown
- 2021-02-17 WO PCT/US2021/018378 patent/WO2022177556A1/en active Application Filing
- 2021-02-17 CA CA3211395A patent/CA3211395A1/en active Pending
- 2021-02-17 AU AU2021428932A patent/AU2021428932A1/en active Pending
- 2021-02-17 CN CN202180095226.2A patent/CN117500781A/zh active Pending
- 2021-02-17 JP JP2023549999A patent/JP2024507822A/ja active Pending
- 2021-02-17 EP EP21710827.3A patent/EP4294789A1/en active Pending
-
2022
- 2022-02-17 AR ARP220100332A patent/AR124907A1/es unknown
- 2022-02-17 TW TW111105793A patent/TW202245746A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024507822A (ja) | 2024-02-21 |
| CA3211395A1 (en) | 2022-08-25 |
| CN117500781A (zh) | 2024-02-02 |
| AU2021428932A1 (en) | 2023-09-21 |
| KR20230148177A (ko) | 2023-10-24 |
| WO2022177556A1 (en) | 2022-08-25 |
| TW202245746A (zh) | 2022-12-01 |
| AR124907A1 (es) | 2023-05-17 |
| IL304974A (en) | 2023-10-01 |
| EP4294789A1 (en) | 2023-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2542847T3 (es) | Formulaciones que comprenden capsaicina, un anestésico local y/o un agente antipruriginoso para el tratamiento del dolor | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| MX2009008228A (es) | N-adamantil benzamidas como inhibidores de la dehidrogenasa 11-beta-hidroxiesteroide. | |
| WO2005039498A3 (en) | Methods of treating cancer with hdac inhibitors | |
| WO2003103603A3 (en) | NEW FORMIATE-TYPE SALT OF O-DESMETHYLVENLAFAXINE | |
| MX2021006265A (es) | Derivados de panteteina y usos de los mismos. | |
| ATE427931T1 (de) | Analgetische verbindungen, deren synthese und pharmazeutische zusammensetzungen, die diese enthalten | |
| MX2023009555A (es) | Composiciones de la forma iv esencialmente pura de n-((r)-2,3-dihidroxipropoxi)-3,4-difluoro-2-(2-fluoro-4-yodo-feni lamino)-benzamida y usos de estas. | |
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| IL276194B2 (en) | Pharmaceutical compounds or preparations containing them for use in the treatment of pain | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| MX2022000143A (es) | Metodos novedosos. | |
| RU2013100383A (ru) | Композиции полиэтиленгликоля для контроля рецидивов лабиального герпеса, генитального герпеса и опоясывающего герпеса | |
| MX2023003846A (es) | Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2023009560A (es) | Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos. | |
| PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| MX2023000868A (es) | Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. | |
| MX2023003459A (es) | Nuevos compuestos. | |
| WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
| TN2011000456A1 (en) | Treatment of pancreatic cancer | |
| KR960700701A (ko) | 파라세타몰 및 l-시스테인 또는 이것의 전구물질을 함유하는 약제조성물(pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof) | |
| MX2022009700A (es) | Compuesto de sulfonamida o sulfinamida que tiene el efecto de inducir la degradacion de la proteina de bromodominio 4 (brd4) y el uso farmaceutico del mismo. | |
| PH12021550471A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| MX2022006877A (es) | Uso de un abridor de canal de potasio kv7 para tratar el dolor. |